Neostigmine

Neostigmine has been studied in 4 papers since 2020: 2 trials and 1 observational study in people, 1 review; 2 in the past year. The newest paper, May 20, 2026: “Ten-year management of acute colonic pseudo-obstruction in a single UK center: a retrospective cohort study”.

Intervention

4 papers study it4 more mention it8 findingsUpdated

PubChemChEBIMeSH

See all 8 papers on neostigmine

At a glance

Independent labs found the same change in people. 3 independent labs in 2 countries; 5 trials, none about aging.

“The incidence of early postoperative cognitive decline in 0.04 mg/kg and 0.02 mg/kg groups was 10 and 15.7%, respectively, which were significantly lower than those in the control group (P = 0.013).”
The effects of neostigmine on postoperative cognitive function and inflammatory factors in elderly patients - a randomized trialBMC geriatrics2020doi:10.1186/s12877-020-01793-4

1 of its findings points the other way.

Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 2 countries
  • 1 finding against
  • 5 trials, none about aging
  • Funders: Dalian Medical University and 1 more
  • Human trial2
  • Humans1

Studies in people

2 studies gave neostigmine to people and measured what changed.

What changedDesignPeopleSource

down: Lowers the risk of postoperative cognitive dysfunction-22% (95% CI, -37 to -7)

Randomized trial7 days118 people≥65 yearsOlder adultsAnesthesia and analgesia, Dec 15, 2023

down: Lowers the risk of early postoperative cognitive decline10% and 15.7% incidence versus control; P = 0.013

down: Decreases extubation timesignificantly shorter than control; P < 0.001

no change: Has no effect on peripheral inflammatory factors

Randomized trial132 peopleelderlyOlder adults; elderly patients after radical gastrointestinal cancer surgeryBMC geriatrics, Oct 6, 2020

What did studies of neostigmine find?

4

Studies of neostigmine measured 4 outcomes, among them BDNF, oxidative stress and ROS signaling and peripheral inflammatory factors.

BDNF

upin humans1

1 study
  1. Neostigmine increases BDNF in humans (P = .013).

    “SOD and BDNF levels were increased ( P = .036 and .013, respectively) in the neostigmine group compared to the control group on the first day after surgery.”

    Human trialserum0.04 mg/kg

    Influence of Neostigmine on Early Postoperative Cognitive Dysfunction in Older Adult Patients Undergoing Noncardiac Surgery: A Double-Blind, Placebo-Controlled, Randomized Controlled Trial

    Anesthesia and analgesia

More on BDNF

Oxidative stress and ROS signaling

downin humans1

1 study
  1. Neostigmine inhibits oxidative stress and ROS signaling in humans (P = .016).

    “Postoperative plasma MDA levels were significantly lower ( P = .016)”

    Human trialplasma0.04 mg/kg

    Influence of Neostigmine on Early Postoperative Cognitive Dysfunction in Older Adult Patients Undergoing Noncardiac Surgery: A Double-Blind, Placebo-Controlled, Randomized Controlled Trial

    Anesthesia and analgesia

More on Oxidative stress and ROS signaling

Peripheral inflammatory factors

no changein humans1

1 study
  1. Neostigmine showed no clear effect on peripheral inflammatory factors in humans (elderly patients after radical gastrointestinal cancer surgery).

    “In elderly patients, 0.02-0.04 mg/kg neostigmine could significantly reduce the incidence of early postoperative cognitive decline without affecting peripheral inflammatory factors.”

    Human trialelderly patients after radical gastrointestinal cancer surgeryperipheral blood0.02-0.04 mg/kg

    The effects of neostigmine on postoperative cognitive function and inflammatory factors in elderly patients - a randomized trial

    BMC geriatrics

More on Peripheral inflammatory factors

Extubation time

downin humans1

1 study
  1. Neostigmine decreases extubation time in humans (elderly patients after radical gastrointestinal cancer surgery) (significantly shorter than control; P < 0.001).

    “The extubating and PACU times in 0.04 mg/kg and 0.02 mg/kg groups were significantly shorter than those in the control group (P < 0.001).”

    Human trialelderly patients after radical gastrointestinal cancer surgery0.02 or 0.04 mg/kg

    The effects of neostigmine on postoperative cognitive function and inflammatory factors in elderly patients - a randomized trial

    BMC geriatrics

What is neostigmine linked with?

2

Studies link neostigmine with 2 measures: postoperative cognitive dysfunction and early postoperative cognitive decline.

Postoperative cognitive dysfunction

downin humans2upin humans1OR 0.31–1.74

2 studies
  1. Neostigmine lowers the risk of postoperative cognitive dysfunction in humans (-22% (95% CI, -37 to -7)).

    “Patients receiving neostigmine had a significantly reduced incidence of POCD compared to patients who were treated with placebo on the first day after surgery (-22%, 95% confidence interval [CI], -37 to -7)”

    Human trial0.04 mg/kgn = 118

    Influence of Neostigmine on Early Postoperative Cognitive Dysfunction in Older Adult Patients Undergoing Noncardiac Surgery: A Double-Blind, Placebo-Controlled, Randomized Controlled Trial

    Anesthesia and analgesia

  2. Neostigmine lowers the risk of postoperative cognitive dysfunction in humans (postoperative general anesthesia with neuromuscular blockade) (OR 0.31, 95% CI 0.15-0.63).

    “administration of a higher dose (≥0.04 mg/kg) was associated with reduced POCD incidence compared to a lower dose (<0.04 mg/kg) (OR 0.31, 95% CI 0.15-0.63, p = 0.001)”

    Reviewpostoperative general anesthesia with neuromuscular blockade≥0.04 mg/kg vs <0.04 mg/kg

    Effect of Reversal Agents on Postoperative Cognitive Disorders Following General Anesthesia in the Elderly Population: A Systematic Review and Meta-Analysis

    Diagnostics (Basel, Switzerland)

  3. Neostigmine raises the risk of postoperative cognitive dysfunction in humans (postoperative general anesthesia with neuromuscular blockade) (OR 1.74, 95% CI 1.00-3.02).

    “neostigmine was associated with a higher risk of POCD than sugammadex (OR 1.74, 95% CI 1.00-3.02, p = 0.05)”

    Reviewpostoperative general anesthesia with neuromuscular blockaden = 795

    Effect of Reversal Agents on Postoperative Cognitive Disorders Following General Anesthesia in the Elderly Population: A Systematic Review and Meta-Analysis

    Diagnostics (Basel, Switzerland)

More on Postoperative cognitive dysfunction

Early postoperative cognitive decline

downin humans1

1 study
  1. Neostigmine lowers the risk of early postoperative cognitive decline in humans (elderly patients after radical gastrointestinal cancer surgery) (10% and 15.7% incidence versus control; P = 0.013).

    “The incidence of early postoperative cognitive decline in 0.04 mg/kg and 0.02 mg/kg groups was 10 and 15.7%, respectively, which were significantly lower than those in the control group (P = 0.013).”

    Human trialelderly patients after radical gastrointestinal cancer surgery0.02 or 0.04 mg/kg

    The effects of neostigmine on postoperative cognitive function and inflammatory factors in elderly patients - a randomized trial

    BMC geriatrics

More on Early postoperative cognitive decline

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 1May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 04 papers in 12 months